StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

Equities researchers at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

GLMD stock opened at $0.36 on Wednesday. Galmed Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $7.80. The business’s 50 day moving average price is $0.36 and its two-hundred day moving average price is $0.38. The company has a market capitalization of $1.83 million, a price-to-earnings ratio of -0.11 and a beta of 0.87.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.